Tagged with S

Boehringer Ingelheim Indonesia After 20 years experience with Boehringer Ingelheim, what would you say are the main specificities of the Indonesian pharmaceutical industry? Indonesia differs some what from other Asian countries, starting from being a non reimbursement market with a very large population, to people having a small disposable income. Indonesia also has…

Korea Drug Research Association (KDRA) What was the vision behind the creation of the Korea Drug Research Association and its main role in the pharmaceutical sector? Until the middle of the 1980s when Korea Drug Research Association (KDRA) was established, the Korean pharmaceutical industry did very little in terms of innovation activities in R&D. They…

IDS Distribution IDS Distribution is part of an Asian, globe spanning Distribution Company. How does being part of a large, regionally specialized player help IDS Distribution in Indonesia? The company’s regional presence is quite strong. When I first began working at IDS Distribution, I wasn’t sure about the right way to grow…

Basilea You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea in June 2007 I was captivated by its plans to implement commercial operations in different countries to what was a…

Euticals group After a long experience at BMS, you are since 2002 at the head of Euticals- a well established group consisting of four entities (Euticals, Ambrosia, Prochisa and Pro.Bio.Sint), each of them developing and producing Active Pharmaceutical Ingredients (APIs) by different processes. To begin, could you give us an overview of…

Solvay Italy You have led a successful career within the Solvay Group in various European countries. Looking back at all these international assignments, including you current function of regional Director South Europe, what did you learn from these experiences that you managed to apply to the Italian market? My career has always…

Lundbeck South Korea What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started out as a small organization, working through our local partner Whanin. In October that same year we managed to launch…

Sanofi Aventis South Korea You have been in S. Korea for a little over a year, following international assignments in Vietnam and Thailand. Besides the fact that this is a much bigger market, what is the major difference of the pharma industry in South Korea when compared to Southeast Asia? First of all, I…

Mensa Group Mensa Group is one of the leaders of the pharmaceutical industry in Indonesia. What inspired you to enter the industry and specifically why did you start your venture in the API sector? I was studying pharmaceuticals and my first professional position was also in the pharmaceutical industry. The API business…

generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…

Russia   When the Russian Federation emerged from the former USSR in 1991 all the structures of the past social net that provided for the complete healthcare needs of citizens were just a memory of the past – nothing was left when the centralized distribution of medication of the former USSR…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Russia. Prepared in association with Lidings, a leading global law firm, this is an extract from The Pharma Legal Handbook: Russia, available to purchase here for GBP 99.     1. What is the definition of Rare Diseases…